Sepracor - Scientific Abstracts : BROVANA® (arformoterol)

1. Hanrahan J, Sciarappa K, Baumgartner RA. Nebulized arformoterol, a long-acting b2-adrenergic bronchodilator, in patients with COPD. Critical Care Medicine Dec. 2006;(34):12:A95 (Abstract).

2. Zhou D, Huo M, Hsu SH, Hsu R, Maier G, Gu Z. Determination of (R,R)-formoterol and (S,S)-formoterol in human plasma using chiral liquid chromatography-tandem mass spectrometry. AAPS Journal 2006;8(S2):W4004 [Abstract].

3. Hanrahan JP, Sahn SA, Fogarty CM, Sciarappa K, Baumgartner RA. Efficacy of nebulized arformoterol in COPD: results from two prospective phase 3 clinical trials. Respiratory Care 2006;51(11):1321 [Abstract].

4. Donohue JF, Hanrahan JP, Grogan DR, Curry L, Sciarappa K, Baumgartner RA. Nebulized arformoterol in COPD: COPD exacerbations in elderly patients from two pooled phase 3 trials. Presented as a poster at American Society of Consultant Pharmacists annual meeting, November 15 - 18, 2006 in Phoenix, AZ. [Abstract].

5. Hanrahan JP, Sahn SA, Busse W, Sciarappa K, Baumgartner RA. Efficacy of nebulized arformoterol, a long-acting b2-adrenergic bronchodilator, in patients with COPD. International Pharmaceutical Abstracts 2006 [Abstract].

6. Hanrahan JP, Sahn SA, Fogarty CM, Sciarappa K, Baumgartner Ra. Efficacy and safety of arformoterol in COPD: a prospective phase 3 clinical trial. Proceedings of the American Thoracic Society 2006;3:A847 [Abstract].

7. Baumgartner RA, Razzetti A, Claus R, McVicar W, Hanrahan JP. A crossover dose-ranging study of arformoterol in patients with COPD. Proceedings of the American Thoracic Society 2006;3:A847 [Abstract].

8. Hanrahan JP, Busse W, Smith WB, Sciarappa K, McVicar WK, Baumgartner RA. Efficacy and safety of nebulized arformoterol in COPD: A prospective phase 3 clinical trial. Chest 2006;130(4):181S [Abstract].

9. Hanrahan JP, Sahn S, Busse W, Sciarappa K, Baumgartner RA. Efficacy of nebulized arformoterol, a long-acting b2-adrenergic bronchodilator, in patients with COPD. European Respiratory Journal 2006;28(Suppl 50):215S [Abstract].

10. Hanrahan JP, Kerwin E, Cheng H, Grogan DR, Baumgartner Ra. Arformoterol in COPD: safety results from two pooled Phase 3 trials. European Respiratory Journal 2006;28(Suppl 50):428S [Abstract].

11. Maier G, Kharidia J, Hanrahan JP, Hsu R, Jaworowicz D, Cirincione B, Owen J, Grasela T. Exposure-response relationship for nebulized arformoterol in subjects with COPD. European Respiratory Journal 2006;28(Suppl 50):427S [Abstract].

12. Maier G, Kharidia J, Hanrahan JP, Hsu R, Jaworowicz D, Cirincione B, Owen J, Grasela T. Population pharmacokinetics of nebulized arformoterol in subjects with COPD. European Respiratory Journal 2006;28(Suppl 50):427S [Abstract].

13. Gu Z, Zhou D, Huo M, Hsu R, Hsu R, Maier G. Determination of in vivo chiral inversion of arformoterol to its diastereoisomers, (s,s)- formoterol, (r,s)- formoterol, and (s,r)- formoterol, by highly sensitive and specific LC/MS/MS methods in human plasma. Presented as a poster at the New England Drug Metabolism Discussion Group, June 8, 2006, Shrewsbury, MA [Abstract].

14. Barone LM, Ameredes BT, Calhoun WJ, Agrawal DK. The effect of the enantiomers of formoterol on inflammatory and constrictory properties in human airway smooth muscle cells. Presented as a poster at the North East Smooth Muscle Society annual meeting 2006, Boston, MA [Abstract].